5.8 Manufacture and skincare products, cosmetics, food supplements and medicine used to treat skin diseases segment 9,708 2.2 13,124 3.2 (3,416) (26.0) total 443,248 100.0 417,617 100.0 25,631 6.1 The
32.6 Debt Service Coverage 904.1 4.4 103.9 4.6 Total Debt to Equity 0.2 0.4 0.2 0.4 * calculated by using earnings of current quarter to be estimated for annual earnings ** based on only cost of medicine
operations for 2nd Quarter of 2017 decreased to 71.69%, while it was 74.38% for the 2nd Quarter of 2016. These resulted from the efficiency of medicine and medical supplies cost management, introducing an
personnel to support its expansion such as Cardiac Medicine department and Opthalmology department. Selling Expenses For the 6-month periods of 2015 and 2016 , the Company and its subsidiary incurred selling
Totabl Debt to Equity 0.13 0.25 * based on only cost of medicine & medical supplies
medicine & medical supplies
53.7 Debt Service Coverage 673.5 10.1 Total Debt to Equity 0.2 0.3 * calculated by using earnings of current quarter to be estimated for annual earnings ** based on only cost of medicine & medical
and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31
rehabilitation services for patients with diabetes. Kasemrad International Hospital Rattanathibeth opened an Advanced Internal Medicine on the 2nd floor with a team of doctors and personnel who are specialized in
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug